Best Practices in How Oncologists and Pathologists Can Work Together to Optimize Biomarker Testing for their Patients with Cancer
Dr Sanjiv Agarwala describes best practices developed at St. Luke’s Cancer Center, where a committee has been formed in which clinicians and pathologists meet to reach consensus on reflex testing of molecular biomarkers, as well as the value of biomarker testing in enhancing patient care.
Biomarker Data in Melanoma Presented at ASCO 2018 Are Largely Extensions of Previous Studies Rather Than New Discoveries
Dr Sanjiv Agarwala argues that much of the biomarker data in melanoma presented at ASCO 2018 are around the value of PD-L1 testing; however, even PD-L1–negative melanoma patients seem to respond to anti–PD-1 therapy, although some studies suggest PD-L1–negative patients may be better candidates for combination immunotherapy.
Dr David Spigel discusses challenges and solutions to incorporating cancer biomarkers into patient care, including finding pathology resources to do the testing, issues around reimbursement, and educating colleagues on the value and operational aspects of biomarker testing in delivering personalized therapy to patients with cancer.
New Clinical Trial Data in Advanced Melanoma Presented at ASCO 2018: How Will it Change How You Practice?
Dr Sanjiv Agarwala talks about exciting new results presented at ASCO 2018 in melanoma, including the durability of anti–PD-1 therapy in providing 40% overall survival at 5 years, updates on adjuvant therapy showing superiority of anti–PD-1 over anti–CTLA-4, and new results in combining immunotherapies.
How Oncologists and Pathologists Can Best Collaborate to Provide Precision Medicine for Their Patients
Dr David Spigel reviews 3 of the most important, practice-changing topics at ASCO 2018: new therapies targeting RET in a number of tumor types, a prognostic biomarker assay to predict whether patients with breast cancer will need adjuvant hormonal therapy or chemotherapy, and the minimum level of PD-L1 positivity required to predict outcomes with immunotherapy in lung cancer.
Page 1 of 2
Results 1 - 10 of 17
Results 1 - 10 of 17